Dispatch Bio Launches to Deliver Universal Treatment Across Solid Tumors with Novel Immunotherapy Approach

Dispatch Bio Launches to Deliver Universal Treatment Across Solid Tumors with Novel Immunotherapy Approach

PHILADELPHIA & SAN FRANCISCO--(BUSINESS WIRE)--Jul 23, 2025-

Solid tumors have challenged CAR-T developers. This biotech raised $216 million to test a new approach

Dispatch Bio is developing a universal immunotherapy by trying to install a synthetic protein — called the “flare” antigen — on every cancer cell in a patient's body.

Dispatch emerges with $216M and plans for a ‘universal’ solid tumor therapy

The startup is using elements of gene and cell therapy to create medicines that could be useful against an array of tough-to-treat solid tumors.

Universal Solid Tumor Treatment Launched by Dispatch Bio

Solid tumor treatment pioneer Dispatch Bio announced its official launch today. Its platform comprises technologies from laboratories of several leading experts, including Carl June, MD, Andy Minn, MD, PhD, Chris Garcia, PhD, and Kole Roybal, PhD. Dispatch’s proprietary Flare platform is designed to expand the curative potential of immunotherapies for cancer patients with solid tumors—which make up the vast majority of cancers. The company’s fir…